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Abstract
Background: Choosing a safe disease modifying therapy during the COVID-19 pandemic is challenging. This case
series study was conducted to determine the incidence rate and the course of Covid-19 infection in MS/NMOSD
patients treated with Rituximab.
Methods: In this study, we designed a web-based questionnaire. Baseline information such as patient- reported
walking disability, total number of Rituximab infusions received, delayed injections, occurrence of any relapse, and
the use of corticosteroids during the pandemic were collected. Also, information regarding the Covid-19 pandemic
such as adherence to self-isolation, any recent exposure to an infected individual and the presence of suggestive
symptoms were collected. In case of positive test results, patients were grouped into 2 categories; mild to
moderate and seriously ill and outcomes were evaluated as favorable (improved/ discharged) and unfavorable
(expired).
Results: Two hundred fifty-eight patients with Multiple Sclerosis were enrolled in this study, 9 of the subjects (3.4%)
were confirmed positive for Covid-19, five of which required hospitalizations (55.5%), two patients required ICU
admission (22.2%) and 2 two patients died (22.2%). None of these patients ever mentioned using corticosteroids
during the pandemic. In comparison to MS patients who were not receiving disease modifying therapy (DMT), our
study indicated a higher incidence of Covid-19 infection, higher ratio of serious illness and a higher fatality ratio.
Conclusions: Rituximab seems not to be safe enough during the pandemic.
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Introduction
SARS-CoV-2 also known as Coronavirus disease
COVID-19 has become a public health emergency of
international concern [1], accounting to numerous re-
ported neurological manifestations [2]. Smoking, older
age (> 60 years old), comorbidities, and immunosuppres-
sion are associated with more severe disease [3], how-
ever, it is not clearly defined if patients with multiple
sclerosis (MS) and neuromyelitis spectrum disorders
(NMOSD) are at an increased risk of COVID-19 infec-
tion or at a higher risk of a more severe disease; there-
fore, the COVID-19 pandemic holds additional source of
concern among Neurologists [4–6]. It is believed that
patients with MS are at greater risk of admission in In-
tensive Care Unit (ICU) in case of any infection [7–9],
this stems from the fact that these patients are on
disease-modifying therapies (DMTs), as well as cortico-
steroid therapy during their attacks, which make them
more immunocompromised [3]. DMTs are divided into
two categories; immunomodulators and immunosup-
pressants [7, 10]. Evidence has demonstrated the direct
or indirect role of B cells in the pathogenesis of both MS
and NMO diseases [11, 12]. In this regard, Anti-CD20
monoclonal antibodies (mAbs) targeting CD20, as B-
cell-depleting therapies, have been demonstrated to re-
duce disease activity in both diseases [13–15]. These
treatment options have been suggested as current im-
munosuppressive disease modifying therapies (DMTs)
[3, 16]. Particularly, Rituximab (RTX), a chimeric mono-
clonal antibody directed at CD20 positive B lymphocytes
is considered a selective immunosuppressant used in dif-
ferent in clinical practice (500–1000mg, every 3–6
months, or on demand at B cells detection of ≥2% of B
cells) [7–10, 17]. Recent real- world experiences have
shown that patients with either NMO or MS disease
benefit efficiently from RTX with favorable safety and
cost-effectiveness profile [17–20]. However, It has been
suggested that the risk of serious infection for patients
with MS or NMOSD varies depending on the DMTs be-
ing used. More efficient DMTs such as Rituximab might
be associated with a higher risk of infection [8, 9] but
some authorities are against this assumption [3, 21]
causing uncertainties over the safety of anti-CD20 anti-
bodies during COVID-19 pandemic [3, 21]. The inci-
dence rate of COVID-19 infection and the course of the
illness among patients using Rituximab during the out-
break is still undefined due to scarce data, while current
guidelines do not provide definitive recommendations
[4, 22]. Therefore, it is crucial to conduct a study to col-
lect information in order to evaluate the clinical status
of these patients and to assess the epidemiological and
clinical parameters of COVID-19 patients with MS or
NMOSD undergoing treatment with Rituximab. This
study, along with other ongoing studies will hopefully
provide us with more definitive evidences in the context




In this analytical case series study, patients diagnosed
with MS or NMOSD who were referred to the 3 hospi-
tals in Tehran at the time the first case of COVID-19
pneumonia was reported in February 2020 until October
2020 were assessed. Patients that received Rituximab
therapy as a DMT and have received at least one full
dose before the COVID-19 pandemic were included in
the study while patients that received the first dose of
Rituximab during the pandemic were excluded.
Study design
A web-based (online) questionnaire was used in collect-
ing data from patients and or their caregivers. Initially,
the investigators made their contact with these patients
through a phone call and explained to them the purpose
of the study as well as a detailed explanation on how the
data will be collected. The link of the online question-
naire was then provided to the participants. Where
needed, investigators were ready to help patients to fill
the online-form step by step. In cases of unanswered
phone calls, the researchers will try again to reach to the
patient for 3 more times within the 24-h period, then,
after that the patient will be considered non-responder/
missed data and was deleted from the analysis and in
cases of demised patients, the corresponding caregiver
will be responsible to fill-up the online questionnaire.
The online questionnaire is composed of 2 core sets of
data;(1) the demographic and clinical characteristics of
the disease process and (2) information related to
COVID-19. Part one of the questionnaire, assessed the
following parameters; age, gender, comorbidities (dia-
betes mellitus, hypertension, cardiovascular diseases,
chronic respiratory diseases, chronic kidney diseases and
malignancies), disease duration and patient-reported
walking disability which was assessed with the use of the
Expanded Disability Status Scale (EDSS). Also, in this
part of the questionnaire, information such as; the total
number of Rituximab infusions administered as well as
delayed dosing schedule during the pandemic (extended
interval dosing), any occurrence of relapse, relapse of
symptoms and treatment plan (inpatient or outpatient)
and the use of corticosteroids during the COVID-19
outbreak were collected.
The second part of the questionnaire contain
questions related to COVID-19 disease that include;
self-isolation, any previous close contact with COVID-19
patient and the presence of suggestive symptoms of
COVID-19 infection since the start of the outbreak.
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Patients manifesting two of the most common symp-
toms of COVID-19; fever, cough, shortness of breath
were considered suspicious. In addition, information re-
garding medical and laboratory history and their test re-
sults (positive/negative) were collected. Confirmed
COVID-19 patients are those with positive RT-PCR
assay of nasal and pharyngeal swab specimens or a spiral
chest CT-scan indicative for COVID-19 infection as re-
ported by a physician. Information regarding patient
care management for COVID-19 positive such as
hospitalization, ICU- admission or home based care and
duration of hospital stay were included in this question-
naire, also, the severity of the illness which was divided
into 3 categories based on the CDC guideline (16); mild
to moderate (treated at home with isolation, antibiotics
and hydration), severe (requires hospitalization due to
dyspnea and hypoxia) and critical condition (requires
ICU admission due to respiratory failure, shock or
multi-organ system dysfunction) and lastly, the final out-
come of the disease (recover, discharged or expired) are
all contained in this questionnaire. Favorable outcome
indicates patient’s recovery or discharge from the hos-
pital while unfavorable outcome means that the patient
has expired.
Statistical analysis
Quantitative statistics were described using means and
standard deviations while qualitative data were reported
by their frequencies. Case fatality ratio was calculated via
the proportion of deaths from the COVID-19 disease
compared to the total number of patients diagnosed with
the condition.
Ethical approval
This study was approved by the Research Ethics
Committee, Iran University of Medical Sciences (IUMS)
having a Registration Code: 99–1–20-17,858.
Results
Of the 350 patients assessed through their medical re-
cords, 312 were considered eligible and were invited by
telephone call to participate in the study. Response rate
among eligible individuals was (n = 258, 82.6%). Of these
312 patients, 168 were females (65.1%) and 90 were
males (34.9%). The mean age was 41.31 ± (18–36 years
old). Majority of the subjects reported no comorbidities
(87.6%), 196 (75.9%) received more than 3 doses of ri-
tuximab and 184 (71.3%) expressed that scheduled doses
of injection were not delayed despite the pandemic. Of
the 216 (83.7%) participants who did not receive any
corticosteroids during the pandemic, no relapse was re-
ported, however, out of the 42 (16.3%) patients who re-
ceived corticosteroids, 6 patients (14.3%) reported a
relapse. Results are summarized in Table 1.
Based on the result of the survey, 87.2% followed self-
isolation guidelines and 25 (9.6%) subjects were
considered suspected cases for COVID-19 and after fur-
ther evaluation, 9 (3.4%) of these patients were finally
confirmed positive for corona virus. Patients are indi-
vidually described on Table 2
Patients with confirmed COVID-19 diagnosis con-
sisted of 4 males and 5 females with mean age of 49.22
years old without any comorbidities. No recent relapses
or corticosteroids use was reported by confirmed cases.
Six patients had followed self-isolation and four cases re-
ported recent contact with COVID-19 cases (Table 3).
Five confirmed cases of COVID-19 were admitted to the
hospital of which 2 of these patients were admitted in
ICU. The rest of the patients received home-based care.
Two of the patients died from COVID-19. The Mortality
ratio among patients admitted to hospital was 40%.
Among the study population, the incidence rate of
COVID-19 was 3.4%. The ratio of mild to moderate
illness was 44.4% and the ratio of serious COVID-19 ill-
ness was 55.5%. The ratio of favorable outcome (cured/
discharged) was 77.7% and the case fatality ratio (CFR)
was 22.2% [CI: − 0.049 < p < 0.494] (Table 3).
Results of the study has indicated that age (P-value:
0.530), disease duration (P-value: 0.760) and walking dis-
ability score (P-value: 0.730) have no correlation with
the type of management patients received as an indicator
of severity (Table 3).
Discussion
This is one of the first case series during the COVID-19
pandemic implying unfavorable results of using Rituxi-
mab during the pandemic.
In spite the fact that the majority of COVID-19 cases
in this study experienced mild to moderate illness, the
hospitalization rate (55.5%) and the proportion of pa-
tients with critical conditions (22.2%) who ended up in
ICU in comparison to all confirmed COVID-19 cases
are considered relatively high.
The current study has not made any comparison with
other DMTs. The evidence is also scarce and controver-
sial in this regard. However, the case fatality ratio (CFR)
(22.2%) and the mortality ratio of Covid-19 among hos-
pitalized patients (40%) in this study are much higher
than those of previous reports in patients who were not
receiving rituximab [23, 24]. In their own studies, Rituxi-
mab was related to an increased rate of COVID-19 in-
fection compared to other DMTs [23, 24]. In addition, it
can be noticed from a review that Anti CD-20 therapy is
linked with more hospitalizations (either ventilated or
not) and more deaths in patients with COVID-19 infec-
tion compared to other therapies for multiple sclerosis.
However, the number of not hospitalized patients was
also higher [25].
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On the contrary, it has been suggested in some few re-
ports with a similar design to ours that this drug is not
linked to a greater risk of serious complications of
COVID-19 illness, and they encouraged using Rituximab
in MS patients [3, 8, 26, 27]. But one main limitation of
the mentioned studies are the small sample size, not
comparing with other DMTs, and lack of accurate
COVID-19 confirmation [3].
Regarding predisposing factors, the sample size is in-
sufficient for analysis, but an overview of the medical
background of the infected cases shows that the majority
of these patients have been treated with Rituximab for a
minimum of 2 doses on a prompt and timely manner.
Females were more infected than males but the male
gender experienced more severe disease and had higher
mortality rate. Recent exacerbation and corticosteroids
Table 1 Descriptive Analysis of demographic and clinical data
Parameter (N) Categories Frequency (%)
Gender (258) Female 65.1%
Male 34.9%
Comorbidities (258) Present 12.4%
Absent 87.6%
Disease duration (258) < 5 years 35.7%
5–10 years 29.4%
> 10 years 34.9%
Walking disability (258) Fully ambulatory, self-sufficient, which represents EDSS 0–3 46.8%
Ambulatory for 500 m without aid/rest which represents EDSS 4–4.5 16.3%
Ambulatory for 200 m without aid/rest which represents EDSS 5 14.0%
Intermittent or unilateral constant assistance which represents
EDSS 5.5–6
12.4%
Constant bilateral assistance (canes, crutches, or braces) which
represents EDSS 6.5
6.2%
restricted to wheelchair which represents EDSS 7 4.3%
Total Number of Rituximab injections (258) Once 7.8%
Twice 16.3%
3 times 14.7%
> 4 times 61.2%
Extended interval dosing (258) Yes 28.7%
No 71.3%
Relapse during the pandemic (258) Yes 16.3%
No 83.7%
Relapse management (42) Outpatient 35.7%
Inpatient 9.6%
Not treated 54.7%
Recent corticosteroid use (42) Yes 14.3%
No 85.71%
self-isolation (258) Yes 87.2%
No 12.8%
Contact with COVID-19 Patients (258) Yes 4.3%
Not Aware 95.7%
Suspected Covid-19 infection (258) Yes 9.7%
No 90.3%
Assessment of Covid-19
(RT-PCR or Imaging) (258)
Performed 8.5%
Not performed 91.5%
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use were mostly negative and walking disability was less
than 3 in most cases. Based on our findings, majority of
the study population were extremely health conscious as
indicated by the high percentage (96%) of patients ob-
serving strict self-isolation and promptly responded to
potential symptoms of coronavirus. As noted, both pa-
tients who died of COVID-19 had not followed social
distancing recommendations and had been exposed to a
person with COVID-19.
To explain the results, it is believed that the T cell im-
munity is vital for the control of SARS-CoV-2 infection
[28]. In particular, it has been shown that decrease in
percentage of CD8 T-lymphocytes, and not CD4 cells, is
associated with poor outcome [29]. But, the immunity
against COVID-19 is complex and current studies show
B-cell responses occur concomitantly in patients infected
with COVID-19 disease, and most patients develop neu-
tralizing antibodies after a delay, which are likely to be
effective against SARS-CoV-2 with good clinical results
[30]. Above all, some studies have demonstrated that Ri-
tuximab can also make a reduction in T-lymphocytes,
especially in CD3+, CD4+, and to a lesser degree CD8+
T-cells along with a small subgroup of T-cells expressing
CD20 [31]. This might justify the higher risk of serious
viral infections in susceptible patients [32]. However, it
is controversial whether it causes further decrease in re-
peated cycles of use [33] or not [34].
Regarding the general approach of using DMTs during
the pandemic, recommendations are categorized into
initiation, continuing, delaying, and stopping DMTs.
The International Federation (MSIF) along with MS So-
ciety have recommended not to initiate Rituximab
Table 3 Descriptive statistics of confirmed COVID-19 cases
Parameter ((Mean ± SD/ Q1,Median,Q3) or (#\%)) Treatment strategy
Confirmed cases (9) Home-based care (4) Hospital admission (5)
Age 49.22 ± 7.94 [41–64] 51.25 ± 9.63 [41–64] 47.6 ± 7.02 [42–59]
P-value a: 0.530 b
Sex Male 4 (44.4%) 1 (25%) 3 (60%)
Female 5 (55.6%) 3 (75%) 2 (40%)
Disease duration 9.33 ± 5.31 [4–18] 10.00 ± 6.32 [4–18] 8.80 ± 5.06 [4–15]
P-value a: 0.760 b
Walking disability 1.78 ± 1.30 [1–5] 2.00 ± 2.00 1.6 ± 0.54
P-value a: 0.730 c
Number of Rituximab injections so far Once 0 (0%) 0 (0%) 0 (0%)
Twice 3 (33.3%) 2 (50%) 1 (20%)
Thrice 0 (0%) 0 (0%) 0 (0%)
> 4 doses 6 (66.6%) 2 (50%) 4 (80%)
Extended Interval Dosing Positive 2 (22.2%) 2 (50%) 1 (20%)
Negative 7 (77.7%) 2 (50%) 4 (80%)
Comorbidity Positive 0 (0%) 0 (0%) 0 (0%)
Negative 9 (100%) 4 (100%) 5 (100%)
Recent relapse Positive 0 (0%) 0 (0%) 0 (0%)
Negative 9 (100%) 4 (100%) 5 (100%)
Corticosteroids consumption positive 1 (11.1%) 1 (25%) 0 (0%)
Negative 8 (88.8%) 3 (75%) 5 (100%)
self-isolation Positive 6 (66.6%) 3 (75%) 3 (60%)
Negative 3 (33.3%) 1 (25%) 2 (40%)
COVID-19 contact Positive 4 (44.4%) 1 (25%) 4 (80%)
Negative 5 (55.5%) 3 (75%) 1 (20%)
Final outcome Cured/Discharged 7 (77.7%) 4 (100%) 3 (60%)
Death 2 (22.2%) 0 (0%) 2 (40%)
Incidence Rate Mild to Moderate Condition Serious Condition Case Fatality Rate
3.4% 44.4% 11% 22.2%
a: Comparison between treatment strategies which were finally required for patient’s management; b: Student T-test; c: Mann-Whitney U test
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during the COVID-19 pandemic, but the Global advice
for MS patients during pandemic does not suggest
Rituximab discontinuation. Delaying the next doses of
Rituximab should be individualized and based on
patient-physician shared decision making (SDM) [35–
37] In this respect, Dr. Brownlee [38] has endorsed
delaying the initiation of Rituximab or considering an al-
ternative for patients along with extended interval dos-
ing guided by intermittent assay for CD19 lymphocyte
counts for patients already on treatment. In our study,
since none of the confirmed COVID-19 patients who
were seriously ill had experienced delayed scheduled in-
fusion dates, we cautiously recommend extended inter-
val dosing if there is an immediate need for doing so.
Regarding NMOSD, discontinuation or using
extended-interval dosing in these patients is discouraged,
for the reason that withholding or delaying high efficacy
DMTs might conversely place patients at a higher risk of
relapse, which in turn results in ominous consequences.
This may as well increase the chance of serious COVID-
19 illness indirectly since it is hypothesized that higher
EDSS scores result in less mobility and worsens the
COVID-19 disease outcome [7, 37]. Altogether, thor-
ough medical judgment including risk assessment of
delaying the treatment should be decided individually
and watchful surveillance is suggested.
The strong point of our study is utilization of either
positive PCR or Chest CT results for verifying COVID-
19 diagnosis to avoid missing cases. The limitation of
this study is not comparing these patients with those be-
ing treated with other DMTs. In addition, evaluating
outcomes in patients with extended interval dosing regi-
men is recommended in future observational studies,
considering as well previous and concomitant treatments
if COVID-19 is confirmed.
Conclusion
Patients with MS or NMOSD being treated with Rituxi-
mab may be at an increased risk of COVID-19 infection
and higher possibility of serious illness and mortality.
The idea of extended interval dosing during the
pandemic is encouraged and the important role of self-
isolation and not being exposed to patients with
COVID-19 is suggested.
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